BrainCool Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for BrainCool.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Medical Equipment earnings growth	22.6%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

No updates

Recent updates

How Much Did BrainCool's(NGM:BRAIN) Shareholders Earn From Share Price Movements Over The Last Five Years?

Jan 14

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as BrainCool has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

OM:BRAIN - Analysts future estimates and past financials data (SEK Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
3/31/2024	33	-57	-59	-51	N/A
12/31/2023	27	-61	-67	-61	N/A
9/30/2023	32	-52	-92	-85	N/A
6/30/2023	32	-53	-76	-70	N/A
3/31/2023	28	-52	-64	-57	N/A
12/31/2022	30	-46	-54	-46	N/A
9/30/2022	16	-48	N/A	N/A	N/A
6/30/2022	19	-44	-40	-30	N/A
3/31/2022	34	-42	N/A	N/A	N/A
12/31/2021	23	-39	-35	-24	N/A
9/30/2021	25	-34	N/A	N/A	N/A
6/30/2021	22	-33	-43	-32	N/A
3/31/2021	8	-32	N/A	N/A	N/A
12/31/2020	16	-37	-47	-39	N/A
9/30/2020	17	-46	N/A	N/A	N/A
6/30/2020	15	-50	-48	-44	N/A
3/31/2020	14	-57	N/A	N/A	N/A
12/31/2019	12	-57	-62	-56	N/A
9/30/2019	13	-55	N/A	N/A	N/A
6/30/2019	10	-51	-49	-39	N/A
3/31/2019	7	-44	N/A	N/A	N/A
12/31/2018	9	-39	-37	-25	N/A
9/30/2018	7	-28	N/A	N/A	N/A
6/30/2018	6	-25	N/A	N/A	N/A
3/31/2018	4	-22	N/A	N/A	N/A
12/31/2017	5	-23	N/A	-29	N/A
9/30/2017	4	-21	N/A	N/A	N/A
6/30/2017	3	-20	N/A	N/A	N/A
3/31/2017	3	-18	N/A	N/A	N/A
12/31/2016	3	-13	N/A	-15	N/A
9/30/2016	3	-12	N/A	N/A	N/A
6/30/2016	3	-12	N/A	N/A	N/A
3/31/2016	2	-11	N/A	N/A	N/A
12/31/2015	2	-9	N/A	-12	N/A
9/30/2015	2	-13	N/A	N/A	N/A
6/30/2015	1	-11	N/A	N/A	N/A
3/31/2015	1	-10	N/A	N/A	N/A
12/31/2014	0	-9	N/A	-7	N/A
9/30/2014	N/A	-3	N/A	N/A	N/A
6/30/2014	N/A	-1	N/A	N/A	N/A
3/31/2014	N/A	0	N/A	N/A	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if BRAIN's forecast earnings growth is above the savings rate (1%).

Earnings vs Market: Insufficient data to determine if BRAIN's earnings are forecast to grow faster than the Swedish market

High Growth Earnings: Insufficient data to determine if BRAIN's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if BRAIN's revenue is forecast to grow faster than the Swedish market.

High Growth Revenue: Insufficient data to determine if BRAIN's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if BRAIN's Return on Equity is forecast to be high in 3 years time

BrainCool Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

BrainCool AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 85.763172 million.

BrainCool AB (publ) to Report Fiscal Year 2024 Results on Feb 10, 2025

Full year 2023 earnings released

Braincool AB (Publ) Announces Karolinska Starts the Clinical Study PRINCESS 2 with BrainCool's Product RhinoChill® System

New major risk - Share price stability

BrainCool AB (publ) and University of Freiburg Announces Start of Pivotal Clinical Trial (Cottis 2) for Combined Target Temperature Management and Thrombectomy After Ischemic Stroke

CEO & Director recently sold kr254k worth of stock

Third quarter 2023 earnings released

Braincool AB (Publ) Announces New Clinical Study Evaluating Early Hypothermia Treatment After Cardiac Arrest with the Braincool System and Rhinochill System

CEO & Director recently bought kr53k worth of stock

American Medical Association Approves New Current Procedural Terminology Code for Cryotherapy Using BrainCool's Cooral System

BrainCool AB (publ) Announces New CPT Code from AMA for Cooral® System supports Pathway to Reimbursement in the U.S

CEO & Director recently bought kr62k worth of stock

Second quarter 2023 earnings released

New major risk - Share price stability

Braincool AB (Publ) Introduces Minichill in Japan

Braincool AB (Publ) Announces New Patent Application for Rhinochill Technology Paves the Way for New Possibilities

BrainCool AB (publ) Receives Patent Approval for "Shivering" in the EU for the Product BrainCool System

Braincool AB (Publ) Announces International Clinical Study with Rhinochill®System of Patients with Sudden Cardiac Arrest Obtain Ethical Approval

First quarter 2023 earnings released

BrainCool AB (publ) to Report Q3, 2023 Results on Nov 30, 2023

BraincCool Launches New Commercialization Strategy for Its Breakthrough Product Cooral ®System Aiming for Reimbursement in the U.S

Is BrainCool (NGM:BRAIN) In A Good Position To Invest In Growth?

BrainCool AB (publ) to Report Fiscal Year 2022 Results on Feb 28, 2023

Third quarter 2022 earnings released: kr0.17 loss per share (vs kr0.12 loss in 3Q 2021)

Here's Why BrainCool (NGM:BRAIN) Can Afford Some Debt

No independent directors

BrainCool AB (publ) to Report Q3, 2022 Results on Nov 30, 2022

BrainCool AB (publ) Announces FDA approval of Cooral

Second quarter 2022 earnings released: kr0.18 loss per share (vs kr0.13 loss in 2Q 2021)

We Think BrainCool (NGM:BRAIN) Has A Fair Chunk Of Debt

First quarter 2022 earnings released: kr0.14 loss per share (vs kr0.12 loss in 1Q 2021)

BrainCool AB (publ) to Report Q1, 2022 Results on May 31, 2022

No independent directors

CEO & Director recently bought kr73k worth of stock

CEO & Director recently bought kr195k worth of stock

CEO & Director recently bought kr195k worth of stock

CEO & Director recently bought kr195k worth of stock

Is BrainCool (NGM:BRAIN) A Risky Investment?

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

Second quarter 2021 earnings released: kr0.13 loss per share (vs kr0.15 loss in 2Q 2020)

CEO & Director recently bought kr238k worth of stock

BrainCool AB (publ), Annual General Meeting, Apr 15, 2021

Full year 2020 earnings released: kr0.68 loss per share (vs kr1.43 loss in FY 2019)

BrainCool AB (publ) Receives FDA "Breakthrough Device" Designation for Cooral® System for Prevention of Oral Mucositis

New 90-day high: kr9.17

How Much Did BrainCool's(NGM:BRAIN) Shareholders Earn From Share Price Movements Over The Last Five Years?

Third quarter 2020 earnings released: kr0.12 loss per share

New 90-day low: kr7.00

Braincool AB Announces Statistically Significant Late-Breaking Clinical Data At SMO Virtual Congress 2020

New 90-day high - kr11.24

BrainCool AB (publ) to Report Q2, 2020 Results on Aug 28, 2020

New 90-day high - kr7.15

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies